Loading...
Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
BACKGROUND: Neuroblastoma (NB) is the most frequent extracranial solid tumor in children. More than 50% of patients present with widespread (stage M) or refractory disease. In these patients, event-free and overall survival was improved by the addition of the anti-disialoganglioside antibody dinutux...
Na minha lista:
| Udgivet i: | J Immunother Cancer |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMJ Publishing Group
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7239695/ https://ncbi.nlm.nih.gov/pubmed/32414861 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000540 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|